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Summary
We have used long-range PCR to identify mutations in
the duplicated part of the PKD1 gene. By means of a
PKD1-specific primer in intron 1, an ∼13.6-kb PCR
product that includes exons 2–15 of the PKD1 gene has
been used to search for mutations, by direct sequence
analysis. This region contains the majority of the pre-
dicted extracellular domains of the PKD1-gene product,
polycystin, including the 16 novel PKD domains that
have similarity to immunoglobulin-like domains found
in many cell-adhesion molecules and cell-surface recep-
tors. Direct sequence analysis of exons encoding all the
16 PKD domains was performed on PCR products from
a group of 24 unrelated patients with autosomal dom-
inant polycystic kidney disease (ADPKD [MIM
173900]). Seven novel mutations were found in a screen-
ing of 42% of the PKD1-coding region in each patient,
representing a 29% detection rate; these mutations in-
cluded two deletions (one of 3 kb and the other of 28
bp), one single-base insertion, and four nucleotide sub-
stitutions (one splice site, one nonsense, and two mis-
sense). Five of these mutations would be predicted to
cause a prematurely truncated protein. Two coding and
18 silent polymorphisms were also found. When, for the
PKD1 gene, this method is coupled with existing mu-
tation-detection methods, virtually the whole of this
large, complex gene can now be screened for mutations.
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Introduction
Autosomal dominant polycystic kidney disease
(ADPKD) is a common genetically heterogeneous dis-
order. It has an incidence of ∼1:800 in all populations,
with mutations in the PKD1 gene at 16p13.3 accounting
for ∼85% of cases and with those in the PKD2 gene at
4q21-23 accounting for the remainder (Peters and Sand-
kuijl 1992). A third possible locus, PKD3, remains to
be identified (Paterson and Pei 1998). The phenotype
produced by mutations in either the PKD1 gene or the
PKD2 gene appears to be indistinguishable and consists
principally of progressive renal enlargement and cyst for-
mation leading, in the majority of affected individuals,
to end-stage renal failure (ESRF) in later life. The disease
associated with PKD1-gene mutations appears to be
more severe, with earlier-onset renal failure (Hateboer
et al. 1999). Extrarenal manifestations occur and in-
clude hepatic and pancreatic cysts and cerebral-artery
aneurysms (Watson and Torres 1996). However, marked
variation in the clinical presentation of ADPKD exists
between and within families, suggesting that environ-
mental and genetic factors may contribute to disease
expression. This is supported by the demonstration of
a genetic “two-hit” mechanism in renal- and hepatic-
cyst formation. Germline and somatic inactivating mu-
tations of the PKD1 gene have been identified in cyst-
lining epithelial cells (Qian et al. 1996; Watnick et al.
1998b). Mutations in the PKD2 gene, a 5.5-kb single-
copy transcript, mainly comprise nucleotide substitu-
tions or small deletions/insertions (Mochizuki et al.
1996; Veldhuisen et al. 1997; Pei et al. 1998). The ma-
jority are predicted to cause premature stop codons.
Since ∼70% of the PKD1 gene is present as multiple
highly homologous copies elsewhere on chromosome 16,
the full range of mutations in this gene has yet to be
established (The European Polycystic Kidney Disease
Consortium 1994). The PKD1 gene comprises 46 exons
spanning 52 kb of DNA, with exons 1–32 being dupli-
cated in at least three other transcribed copies (Hughes
et al. 1995). The majority of PKD1-gene mutations iden-
tified therefore lie within the remaining single-copy re-
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gion of the gene (Peral et al. 1996a, 1996b, 1997; Dan-
iells et al. 1998; The Human Gene Mutation Database
Cardiff). Most are nucleotide substitutions and small
deletions/insertions that lead to premature termination
of the predicted protein product.
Exons 33–46, which constitute the single-copy region
of the PKD1 gene, have been analyzed by conventional
mutation-screening methods such as SSCP (Peral et al.
1996b). More recently, attempts have been made to de-
fine mutations in the duplicated part of the PKD1 gene,
by techniques such as the protein-truncation test (PTT)
and long-range PCR (LR-PCR). This has extended the
number of exons examined, but a considerable part of
the 5′ end of the PKD1 gene, including exons 1–15, has
not been fully analyzed. In the first published report of
mutations detected in the duplicated region, Peral et al.
used the PTT and a nonisotopic RNase-cleavage assay
after PKD1-specific reverse transcription–PCR (RT-
PCR), to detect mutations in the duplicated area (Peral
et al. 1997). Six mutations were identified in exons
22–32; three were small insertions/deletions, and three
were nucleotide substitutions (one nonsense). Analysis
of a similar region by LR-PCR, with one primer located
in the single-copy region, has recently identified an un-
usual pattern of PKD1-gene mutation (Watnick et al.
1997). In two individuals, multiple clustered base-pair
changes were seen in exon 23, which would be predicted
to cause multiple amino acid substitutions. These mu-
tations have arisen as a result of a gene-conversion event
between the PKD1 gene and its homologues (Watnick
et al. 1998a). The PTT has also been used to extend
mutation analysis up to and including exon 15 (Roelf-
sema et al. 1996). Although this method will only detect
translation-terminating mutations and not missense mu-
tations, it identified six mutations in exon 15, four of
which were small deletions, in a total of eight mutations
in 155 individuals.
At the present time, only a third of the PKD1 gene
can be completely screened for sequence variants, limi-
ting both the accurate definition of mutational events in
the PKD1 gene and their precise relationship, if any, to
the disease phenotype. A technique that allows the spe-
cific detection of mutations in the remainder of the PKD1
gene is therefore required. The amplification of discon-
tinuous fragments from the 3′ end of exon 15 to exon
46 has already been demonstrated (Peral et al. 1996b,
1997; Watnick et al. 1997, 1998b). With PTT analysis
of exons up to and including exon 15, terminating mu-
tations can also be identified (Peral et al. 1997; Roelf-
sema et al. 1997). However, the detection rate has been
disappointingly low. To study the complete range of
PKD1-gene mutations, the remaining exons, 1–15, their
adjacent intronic sequences, and the PKD1-gene pro-
moter region need to be isolated. We have developed a
method that allows the direct sequence analysis of exons
2–15 and that is a significant step toward achievement
of this aim. Comparison between PKD1-gene sequences
and partial sequences from the homologous genes has
allowed us to identify sequences unique to intron 1 of
the PKD1 gene and to use LR-PCR to amplify a region
including exons 2–15. Direct sequencing of this LR-PCR
product has identified seven novel mutations in regions
encoding the 16 PKD domains in 24 unrelated patients
with ADPKD. The structure of these domains has re-
cently been determined (Bycroft et al. 1999), and so the
likely effect of missense mutations, in addition to the
effect of nonsense and frameshift mutations, may be
predicted.
Patients and Methods
Patients
DNA samples were obtained from 65 patients partic-
ipating in a study to determine genetic and environ-
mental risk factors for cerebral-aneurysm formation in
ADPKD and from patients attending renal and genetics
clinics. Consent for DNA storage and mutation analysis
was obtained in all cases. DNA was extracted from
whole blood by the Puregene kit (Gentra), according to
the manufacturer’s protocol. RNA was extracted from
peripheral-blood lymphocytes by TRIzol Reagent
(GibcoBRL). Approval for this work had been obtained
from the relevant local research-ethics committees.
Sequence Alignments
Alignments of the 52-kb PKD1 genomic sequence
(GenBank accession number L39891) and 127 kb of
sequence containing several of the duplicated PKD1-
gene sequences (GenBank accession number AC002039)
was performed by DOTTER (Sonnhammer and Durbin
1995) (fig. 1).
PCR Amplification of DNA and RNA
Total RNA was reversed transcribed by EXPAND
reverse transcriptase (Boehringer Mannheim) and ran-
dom hexamers, according to the manufacture’s guide-
lines. All LR-PCR reactions on samples from 65 patients
were performed by the EXPAND PCR System (Boeh-
ringer Mannheim) with buffer system 3 (2.25 mM
MgCl2 with detergents), according to the manufacturer’s
protocol. Conventional PCR utilized Bio-X-Act (Bio-
line). A total of 200 ng of genomic DNA was used in
all LR-PCR reactions. LR-PCR was performed with 50-
ml reactions in 0.2-ml thin-walled PCR tubes and a PTC-
200 thermocycler (MJ Research). The cycling parame-
ters and primers used in the LR-PCR reactions are
detailed in table 1. For LR-PCR reactions in buffer sys-
tem 3, 500 mM of each dNTP and 300 nM of each primer
were used. The primer sequences used to generate the
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Figure 1 PKD1 genomic sequence (GenBank accession number L39891) and 127 kb of sequence from a BAC clone (GenBank accession
number AC002039) containing part of the duplicated region of the PKD1 gene, aligned by DOTTER (see the Patients and Methods section).
Areas of homology are defined by continuous lines. Two distinct partial copies of the PKD1 gene can be seen. Dotted vertical lines define the
boundaries of regions of homology that are discontinuous with a partial genomic structure of the PKD1 gene. Two regions appear to be unique
to the PKD1 gene, the largest corresponding to a substantial part of intron 1.
PCR products are listed in table 2. To generate additional
sequencing templates from each patient, either LR-PCR
reactions were repeated or regions of interest were am-
plified, by internal nested primers, from purified LR-
PCR templates after 105-fold dilution (fig. 2).
Direct Sequencing of PCR Products
LR-PCR products from a sample of 24 patients were
sequenced. LR-PCR products were purified by Qiagen
PCR clean-up columns, and 150 ng was used in each
42 Am. J. Hum. Genet. 65:39–49, 1999
Table 1
LR-PCR Parameters
5-kb Product 10-kb Product 13-kb Product
Primers 17Ext22R 17Ext27R 17.1L30Ext
PCR parameters 94C for 2 min; 10 cycles of 94C
for 10 s, 61C for 30 s, and 68C
for 4 min; 20 cycles of 94C for
10 s, 61C for 30 s, and 68C for
4 min; 68C for 7 min; 20 s per
cycle
94C for 2 min; 10 cycles of 94C
for 10 s, 60C for 30 s, and 68C
for 10 min; 20 cycles of 94C for
10 s, 60C for 30 s, and 68C for
10 min; 68C for 7 min, 20 s per
cycle
94C for 2 min; 10 cycles of 94C
for 10 s, 68C for 30 s, and 68C
for 12 min; 20 cycles of 94C for
10 s, 68C for 30 s, and 68C for
12 min; 68C for 7 min, 20 s
per cycle
[Mg2] 2.25 mM 2.25 mM 2.25 mM
Annealing temperature 61C 60C 68C
Product positiona 17049–21960 17049–27251 16947–30620
Exact size 4,911 bp 10,202 bp 13,673 bp
a Positions are genomic positions according to Burn et al. (1995) (GenBank accession number L39891).
sequencing reaction. PCR products were purified from
agarose gels, by the QIAquick gel-extraction kit. All
sequencing reactions were performed by the Applied
Biosystems (ABI) BigDyeTerminator Cycle Sequencing
Ready Reaction Kit, according to the manufacturer’s
guidelines. Modifications to this protocol included total
reaction volumes of 10 ml and the use of BigDye buffer
(catalog number 361028C) to dilute the BigDye re-
action mix two- to four-fold. Cycle sequencing param-
eters were 25 cycles of 95C for 15 s, 55C for 15 s, and
60C for 4 min, with PCR and walking primers to span
the regions of interest (table 2). Reaction products were
ethanol precipitated, resuspended in formamide-loading
buffer, and electrophoresed on an ABI 373A automated
sequencer (fig. 3). Sequences were compared both be-
tween all individuals and with the published cDNA and
genomic sequences.
Results
An alignment of the PKD1 genomic sequence against
a partial sequence of the PKD1-gene homologous region
revealed areas of extensive but discontinuous homology
(fig. 1). Two incomplete copies of the PKD1 gene were
identified in a 127-kb bacterial artificial chromosome
(BAC) clone (GenBank accession number AC002039).
Two regions of the PKD1 genomic sequence were not
duplicated in either of the homologous copies. This sug-
gested that the other homologous genes may have a sim-
ilar structure and that these regions would be unique to
the PKD1 gene. The largest region was located in intron
1, in the vicinity of nucleotide position ∼8,000-18,000.
Short regions close to the 3′ boundary of this area were
analyzed by PCR, to determine whether they were
unique to the PKD1 gene. Both the radiation hybrid,
145.19, which contains only the PKD1 gene, and the
rodent-human somatic cell hybrid, 23HA, which con-
tains only the homologous region, were used as tem-
plates, as described elsewhere (Watnick et al. 1997).
Primer pair 17F and 17.5R (table 1) produced a single
product of expected size (∼480 bp), both with normal
human genomic DNA and with DNA from cell line
145.19 only. Amplification with 17.5F and 18R pro-
duced a product from all three DNA samples, demon-
strating that primer sequence 17.5F was present in the
duplicated region but that primer sequence 17F was
unique to the PKD1 gene. With a series of primers in
the duplicated region (22R in intron 6, 27R in intron
14, and 30R at the 3′ end of exon 15), PCR products
of increasing length were generated by primer 17Ext (a
modified 17F primer with a higher melting temperature,
for use in the LR-PCR reactions) (fig. 2). In the 13-kb
LR-PCR reaction, primer 17.1L eventually replaced
17Ext, since it consistently produced a cleaner product
when multiple PCR reactions were prepared. Primer-se-
quence modifications were also confirmed as being spe-
cific to the PKD1 gene by the same hybrid-DNA samples
(fig. 4). For nested PCR reactions that were used to gen-
erate further sequencing templates, a 105-fold dilution
of the 13-kb template was used. At this dilution, no
amplification of genomic DNA carried over from the
first round of PCR was detectable by primers in the
single-copy region of the PKD1 gene and primers 5′ to
the 13 kb template in the duplicated region (data not
shown). A single 13-kb template could therefore be used
to generate sufficient sequencing templates for all reac-
tions (fig. 2).
The longest PCR product generated during this study
was 13.6 kb, which extended from intron 1 to the 3′
end of exon 15 and contained ∼50% of the PKD1-gene
coding sequence. Exons 5 and 11-15 constitute 42% of
the PKD1-gene coding sequence and encode all 16 copies
of the PKD domain. The coding region and adjacent
splice sites of these exons were analyzed by direct se-
quencing in a sample of 24 patients, to define the range
of mutations in this region of the PKD1 gene and to
predict the likely effect that missense mutations would
have on the structure of this domain.
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Table 2
Primer Sequences and PCR Conditions
PCR Product/Type and Primer (Sequence) Genomic Position
Annealing
Temperature
(C)
Mg
(mM) PCR/Sequencing
Product
Length
(bp)
5 kb:
17Ext (CCC AGC GTC TCA TCT GTC TGG)a 17049–17069 61 2.25 LR-PCR 4,911
22R (CTG CAT CTG CAG AGC TGA CAG) 21939–21960
10 kb:
17Ext 27R (CAC AGG TGT AGC AGC ACT GAG) 27231–27251 60 2.25 LR-PCR 10,202
13 kb:
17.1F (GCA TAG GCT CTC TGA GTG TCC CAC A)a 16947–16971 68 2.25 LR-PCR 13,673
30Ext (CCT CCA AGT AGT TGC GCT GTG ATC G) 30596–30620
Exon 15:
PKDD4 (GAC GCT GCC ATG GCT GTG) 26222–26239 55 2.25 PCR 4,394
30R (CAA GTA GTT GCG CTG TGA TCG) 30596–30616
RT PCR:
RTexon13F (ATG CCA CGC TAG CAC TGA CG) 26432–26452 58 1.5 RT-PCR 355
PKD15.2R (CGT GTT GTT GAC CTC CAG GC) 27680–27699
ARMS PCR:
PKDD1.F (TCC AGT GCC TCC TTT GCC) 21001–21019 52 2 ARMS-PCR 276
971WT (GCC CAG GCA GCA CAT ATC) 21260–21277
971Mut (GCC CAG GCA GCA CAT ATA) 21260–21277
17F (CAG CGT CTC ATC TGT CTG G)a 17051–17069 55 1.5 PCR 481
17.5R (GAC TAT GGC TCC GCA GGT) 17015–17532
17.5F (AGA CCT GCG GAG CCA TAG TC) 17513–17532 61 1.5 PCR 465
18R (GCA GTG AGC TGA GAT CGC AC) 17859–17978
PKDD1.F (TCC AGT GCC TCC TTT GCC) 21001–21019 Sequencing
PKDD2.F (GCA CAA CCT CTC CTG CAG) 24682–24698 Sequencing
PKDD3.1.F (CGA CAG GCT AAG GGC AGA) 25931–25948 Sequencing
PKD15.1 (CTC AGT GCT GCT ACA CCT GT) 27231–27251 Sequencing
PKD15.2 (GCC TGG AGG TCA ACA ACA) 27680–27699 Sequencing
PKD15.3 (TCT TCG ACT GGA CCT TCG G) 28085–28103 Sequencing
PKD15.4 (TGC TGC CAA TGA CTC AGC C) 28467–28485 Sequencing
PKD15.5 (CTG TGA CCG CTG CAC GCC) 28862–28879 Sequencing
PKD15.6 (GAC TGC ACC ATG GAC TTC) 29234–29251 Sequencing
PKD15.7 (CAA TGT GAG CTG GTG CTG G) 29608–29626 Sequencing
PKD15.8 (CAT CGT GGT GCT GGA GGC) 30001–30019 Sequencing
PKDD10 (CCA CGC TTA CAA CAG CAC AG) 28653–28672 Sequencing
PKDexon5 (GGA GCC TGT GAG TGC GGC) 20731–20748 Sequencing
PKDexon11 (CAT GAC CGT GAG GAC GTG AT) 24312–24331 Sequencing
PKDexon14 (CGT GAC TGC AGA GTG GAG C) 26706–26724 Sequencing
a PKD1 gene–specific primer.
Mutations Identified by LR-PCR
A single 13-kb LR-PCR product (patient 8) produced
two distinct fragment sizes on conventional agarose-gel
electrophoresis. Further analysis of patient 8’s genomic
DNA by LR-PCR primers 17Ext and 22R demonstrated
the presence of both a normal-size 5-kb band and an
∼2-kb band (fig. 5). Direct sequencing of the smaller
band revealed a deletion extending from within intron
1 to exon 5 (g18177–21076del). In a sample of 64 13-
kb LR-PCR products from other patients with ADPKD,
which were resolved on 0.6% agarose gels, no other
altered band sizes were detected.
Mutations Identified by Direct Sequencing
Exons 5 and 11–15 were sequenced in the sample of
24 patients with ADPKD who were used in this study.
The use of small-volume sequencing reactions and di-
luted BigDye terminators had no effect on sequence
quality of purified PCR products, and readings 1400 bp
were routinely achieved (see the Patients and Methods
section). All sequence variants were confirmed on both
strands of two independent LR-PCR samples, to elimi-
nate the possibility of LR-PCR artifacts. A total of 26
sequence variations were identified; 18 were silent poly-
morphisms, and the remaining 8 were possible pheno-
type-modifying mutations (tables 3 and 4).
Four of the eight possible phenotype-modifying mu-
tations identified by direct sequencing were predicted to
cause a prematurely truncated protein (table 3) and were
therefore very likely to be pathological. They consisted
of a 28-bp deletion (6434–6461del), a single nonsense
mutation (Q1922X), a single nucleotide insertion
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Figure 2 PKD1-gene exons 2–15, which can be specifically am-
plified from a unique primer in intron 1. A, PKD1-gene region that
has been amplified by LR-PCR, shown as fragments of increasing
length (line a). The shorter, 5-kb product spans exons 2–6, the 10-kb
product spans exons 2–14, and the 13-kb product spans exons 2–15.
Also shown are other PCR products (lines b and c) amplified from the
duplicated region that have been reported by Watnick et al. (1997 [line
c], 1998b [line b]). B, 0.6% Agarose gel resolving LR-PCR products.
Lane 1, 1-kb marker. Lane 2, 5-kb LR-PCR product. Lane 3, 10-kb
LR-PCR product. Lane 4, 13-kb LR-PCR product. Lane 5, Exon 15
amplified from a 13-kb template by primers PKDD4 and 30R. Lane
6, lHindIII marker.
Figure 3 Direct sequence analysis of the PKD1 gene in patient
26, demonstrating a single T insertion at position 5109. The resulting
frameshift introduces 23 novel amino acids after position 1633.
(4898–4899insT) (fig. 3), and a splice acceptor–site mu-
tation in intron 14 (g27406GrA; IVS141GrA) (table
2). Frameshift mutation 4898–4899insT occurred in co-
don 1633 and resulted in the addition of 23 novel amino
acids before a premature stop codon. Mutation
6434–6461del resulted in five novel amino acids after
codon 2144, before premature termination. When both
RT-PCR on total RNA isolated from peripheral-blood
lymphocytes and primers in exons 13 and 15 (table 2)
were used, the splicing mutation IVS141GrA
(g27406GrA) was shown to result in intron retention
(fig. 5). Direct sequence analysis of RT-PCR products
demonstrated the retention of intron 14, which would
result in the addition of three novel amino acids before
a premature stop codon after exon 14.
The remaining four possible mutations were missense
mutations—R324L, L845S, W1399R, and P1786L. On
further analysis, two of these four—that is, W1399R
and P1786L, located in PKD domains 8 and 12, re-
spectively—were found to be coding polymorphisms;
W1399R (4195TrC) was detected in two families with
ADPKD, did not segregate with the disease phenotype
in one family, and was present in 6 of 120 normal chro-
mosomes analyzed for the presence of a newly created
NciI site, and P1786L (5357CrT) was confirmed in pa-
tient 41’s genomic DNA by the detection of a newly
created BspMI site. However, it was found in only two
of three affected siblings and eventually was shown to
have been inherited from the unaffected parent. It was
absent from 120 normal chromosomes analyzed and was
not found in any other unrelated patients with ADPKD
who were studied. One of the remaining two missense
mutations was located in a PKD domain (fig. 6). In pa-
tient 32, a GrT substitution was found at position 971.
This resulted in a change from a basic Arg to a neutral
hydrophobic Leu in PKD domain 1 (R324L). Its pres-
ence in this patient’s genomic DNA was confirmed by
an amplification-refractory mutation system (ARMS)
PCR assay (table 2). No other family members were
available for study, and the patient’s three young chil-
dren had not been screened for renal cysts. The final
missense mutation, a TrC substitution at position 2534,
predicted a change from a neutral and hydrophobic Leu
to a polar Ser at position 845, six residues N-terminal
to the start of PKD domain 2. It was demonstrated in
the patient’s genomic DNA by detection of the loss of
an StyI site. The mutation was not found in the patient’s
unaffected daughter. Both of these missense mutations
were absent from 120 normal chromosomes and from
all other unrelated patients with ADPKD who were stud-
ied. No patient contained more than a single potentially
pathological mutation in the PKD1-gene region
analyzed.
Discussion
Molecular analysis of families with ADPKD has been
confined mainly to the use of informative polymorphic
markers for linkage analysis. They have been used both
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Figure 4 5-kb LR-PCR product, which is specific to the PKD1
gene. The 5-kb LR-PCR product (from use of primers 17Ext and 22R)
was amplified from normal human genomic DNA as a positive control,
and the specificity of the reaction was determined by use of cell lines
145.19 and 23HA (see the Results section). Lane 1, 1-kb ladder. Lane
2, No-DNA negative control. Lane 3, Human genomic DNA. Lane 4,
23HA DNA. Lane 5, 145.19 DNA. Lanes 6 and 7, 5-kb LR-PCR
product generated by primers 17.5F and 22R, by use of DNA from
145.19 (lane 6) and 23HA (lane 7). This confirms that 23HA DNA
can be amplified and that primer 17.5F is present in the duplicated
region.
Figure 5 A, 5-kb LR-PCR product in patient 8, which shows a
∼3-kb deletion. Amplification of genomic DNA from patient 8 (lane
4) demonstrates two bands—5 kb and 2 kb—compared with the nor-
mal, 5-kb product from the genomic control (lane 3). Lane 1, 1-kb
ladder. Lane 2, No-DNA negative control. Sequencing of the 2-kb
product confirmed a 2.9-kb deletion of the PKD1 gene (see the Results
section). B, RT-PCR analysis of lymphocyte total RNA from patient
43, which shows retention of intron 14. Amplification using primers
in exons 13 and 15 demonstrates a single expected 355-bp RT-PCR
product in a control sample (lane 3) and two products—355 bp and
1,267 bp—in patient 43. Direct sequence analysis of the RT-PCR prod-
ucts confirmed that this was due to retention of intron 14 in the larger
fragment. Lane 1,123-bp marker. Lane 2, No-DNA negative control.
Lane 3, RT-PCR  RT of normal control. Lane 4, RT-PCR  RT in
normal control. Lane 5, RT-PCR  RT in patient 43. Lane 6, RT-PCR
 RT in patient 43.
to determine whether families have linkage to either the
PKD1 gene or the PKD2 gene, in predictive testing of
young individuals with a normal renal ultrasound scan,
and for prenatal diagnosis (Breuning et al. 1990). More-
detailed genetic analysis of the PKD1 gene in affected
and normal individuals has been complicated by the
presence of multiple homologous copies of the PKD1
gene, which have made mutation analysis technically
difficult (Harris et al. 1995). Most reported mutations
are therefore located in the 3′ single-copy region of the
gene. In addition, very few recurrent mutations have
been described, with the majority being private (Daniells
et al. 1998). This suggests that mutations are likely to
be spread throughout the PKD1 gene. In this report, we
have described the use of LR-PCR to identify mutations
in the duplicated 5′ region of the PKD1 gene.
The specific amplification of exons 2–15 was achieved
by use of a primer located in a unique region of intron
1. This was identified by alignment of the PKD1 genomic
sequence with a partial sequence of the homologous re-
gion. This analysis also provided important information
about the organization of the homologous genes. The
BAC clone (GenBank accession number AC002039)
contained two partial copies of the PKD1 gene. Nu-
merous sequence variations were observed between these
copies and the PKD1 gene, and, unexpectedly, regions
of homology between the PKD1 gene and the homol-
ogous genes were clearly discontinuous (fig. 1). Several
regions of the PKD1 gene were therefore potentially
unique if the other homologous genes had a similar
structure. These regions included a considerable part of
intron 1, on the basis of which the unique primer 17Ext
was designed, and the region surrounding the polypyr-
imidine tract in intron 21 (Burn et al. 1995). Complete
sequence analysis of the rest of the homologous-gene
region may permit rapid development of further PKD1
gene–specific reagents.
In previous studies, LR-PCR has been used in the anal-
ysis of the duplicated part of the PKD1 gene, to specif-
ically amplify exons 23–34 and part of exon 15 through
exon 21 (Watnick et al. 1997, 1998b). More than half
the coding sequence, exons 1–15, has therefore not been
systematically analyzed in families with ADPKD. Spe-
cific amplification of exons 2–15 now allows virtually
all exons and adjacent sequences of the PKD1 gene to
be examined. The specificity of the LR-PCR primers used
in this study has been confirmed by use of cell lines
145.19 and 23HA, described above, which contain ei-
ther the PKD1 gene alone or the homologous copies
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Table 3
Mutations in the PKD1 Gene
Patient(s) Mutationa Location Effect on Coding Sequence
8 g18177–21076del Intron 1–exon 5 Frameshift after aa 72
26 4898–4899insT Exon 15 Frameshift after aa 1633
35 6434–6461del Exon 15 Frameshift after aa 2144
43 IVS141GrA Intron 14 Frameshift after aa 1097
32 R324L Exon 5 ArgrLeu at aa 324
33 L845S Exon 11 LeurSer at aa 845
30, 38 W1399R Exon 15 TrprArg at aa 1399
41 P1786L Exon 15 ProrLeu at aa 1786
36 Q1922X Exon 15 Glnrstop at aa 1922
a All mutations except that denoted with the prefix “g” are cDNA positions, according to Hughes et
al. (1995) (GenBank accession number L33234), and the genomic positions are according to Burn et al.
(1995) (GenBank accession number L39891).
Table 4
Polymorphic Variations in the PKD1 Gene
Polymorphisma Location Effect on Coding Sequence
1023C/T Exon 5 A341A
g25134C/T Intron 11
2694A/C Exon 11 A898A
2700G/A Exon 11 P900P
2730C/T Exon 11 D910D
2972T/G Exon 12 V991V
3063T/C Exon 13 G1021G
3111A/G Exon 13 L1037L
3372C/T Exon 15 A1124A
3375C/T Exon 15 S1125S
3864C/T Exon 15 H1288H
4635G/A Exon 15 K1545K
4665A/C Exon 15 A1555A
4674G/A Exon 15 T1558T
5172C/T Exon 15 A1724A
5359C/T Exon 15 L1787L
5485C/T Exon 15 L1829L
5763G/A Exon 15 L1921L
a Positions are as defined in the footnote to table 3.
alone (Watnick et al. 1997). In the absence of the com-
plete sequence of the homologous region, these reagents
have been essential in the definition of many of the locus-
specific reagents now used in PKD1 gene–mutation anal-
ysis. We have also analyzed PKD-domain sequences
from PCR products in which amplification from the ho-
mologous region had also occurred. We consistently
failed to demonstrate the same mutations that had been
identified on the basis of the PKD1 gene–specific LR-
PCR products, presumably because of preferential am-
plification of the multiple homologous genes, providing
further evidence that the primers are specific to the PKD1
gene.
Attempts to amplify a region including exon 21 by
the intron 1–specific primer have, so far, been unsuc-
cessful. The size of this product, ∼17 kb, is technically
feasible, but certain properties of the sequence surround-
ing this region, such as its long polypyrimidine tract,
may prevent efficient amplification. This region of intron
21 may divide the PKD1 gene into two separate halves
suitable for LR-PCR amplification and mutation screen-
ing, unless an RNA-based strategy is employed.
The PCR-based approach described above has advan-
tages over other techniques (Watnick et al. 1997). A
single set of primers can be used to amplify very small
quantities of genomic DNA. This produces, in one re-
action, sufficient template for all future mutation screen-
ing and detection steps and allows the detection of all
sequence variants. We have chosen to directly sequence
the LR-PCR or nested PCR products, in preference to
screening for mutations, for several reasons. Screening
methods such as SSCP, which require multiple further
rounds of PCR amplification of the LR-PCR templates
in order to generate fragments of optimal size for anal-
ysis, are unlikely to have 100% sensitivity and cannot
distinguish between silent polymorphisms, which are
common in the PKD1 gene, and pathogenic mutations.
The PTT will detect only those mutations that result in
a truncated protein and will not detect missense muta-
tions, which constitute an unknown proportion of
PKD1-gene mutations. The PTT is also not suitable for
the study of all exons, depending on either their size or
the availability of RNA templates, and requires several
further experimental manipulations, including the use of
cell-free lysates for protein translation. Direct sequencing
with BigDye, however, can be performed directly on
the LR-PCR product, uses only small amounts (∼150
ng) of DNA and sequencing reagents per reaction, can
be easily adapted to microtiter-plate format, and readily
detects heterozygous mutations (fig. 3). The use of high-
throughput automated sequencers will allow several
hundred sequencing reactions to be analyzed by a single
operator daily. As with other genes containing multiple
exons, this will allow rapid screening of the whole cod-
ing sequence and adjacent intronic sequences, for all
variants, with a high detection rate (Martin et al. 1998).
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Figure 6 PKD domain, which is a b sandwich composed of two
sheets, one containing A, B, and E strands and the other containing
G, F, C, and C′ strands. The positions of R324L (domain 1, E strand),
P1786L (domain 12, FG turn), and W1399R (domain 8, B strand) are
shown superimposed on the structure of PKD domain 1. All amino
acid changes can be seen to affect surface residues. This figure was
prepared by Molscript (Kraulis 1991).
Because of the ability to use small (10 ml) sequencing-
reaction volumes and diluted sequencing reagents, the
costs and time taken to detect mutations, are consid-
erably less for this method than they are those for meth-
ods such as PTT. During this study, reagent costs for
LR-PCR and DNA purification that produced sufficient
template for six to eight sequencing reactions were 2£
($3.20)/patient sample. Further sequencing reactions
were performed on template generated by nested primer
sequences and LR-PCR template DNA diluted 105-fold
(table 2). Therefore, a single LR-PCR reaction generated
sufficient DNA for all future applications. Costs for each
sequencing reaction were calculated to be ∼1£ ($1.60),
excluding sequencer-related costs. However, the main
advantage of this technique is the detection of all se-
quence variants in the region being analyzed. This study
has demonstrated a mutation-detection rate of 29% in
a sample of 24 patients. If 85% of these patients have
a mutation in the PKD1 gene, then the detection rate
was 7/20, or 35%, when 42% of the coding region was
analyzed.
The generation of a PKD1 gene–specific LR-PCR
product spanning exons 2–15 now allows a large part
of the duplicated region of the PKD gene to be screened
for mutations. Five of the mutations identified were ei-
ther frameshift or stop mutations and therefore were
clearly pathogenic. In the case of the splicing mutation,
IVS141GrA, the GrA substitution abolishes the 3′
splice-acceptor site of intron 14 and would be predicted
to lead to aberrant splicing. The possible effects of this
mutation include the use of alternative cryptic splice sites
in either intron 14 or exon 15 (several of which can be
predicted), intron retention, or exon skipping. RT-PCR
analysis of peripheral blood–lymphocyte RNA has
shown that retention of intron 14 occurs, producing a
premature stop codon after three novel amino acids are
added to exon 14. It has not been possible to determine
whether the same or additional kidney-specific splicing
events occur.
Although the presence of a truncating mutation is
clearly pathogenic, a determination of the significance
of a missense mutation is more difficult. Established cri-
teria include the absence of other significant mutations
elsewhere in the gene, segregation of the mutation with
the disease phenotype, alteration of conserved amino
acid residues to those with different physical properties,
occurrence on !1% of normal alleles, and the demon-
stration of altered function (Cotton and Scriver 1998).
Clearly, not all of these criteria can be fulfilled for these
missense mutations, and hence their designation as path-
ological may remain uncertain until the rest of the gene
can be completely screened and until definitive func-
tional assays can be performed. Since the function of the
extracellular region of polycystin—and, in particular,
that of the PKD domains—is unknown, the effect of the
missense mutations described in this report can be de-
duced only from both their location in the PKD domain
and their likely effect on structure or ligand binding.
The structure of the PKD domain has recently been
determined (Bycroft et al. 1999). It is a novel protein
domain consisting of a b-sandwich or immunoglobulin
(Ig) fold (fig. 6). Two b-sheets, one of which has three
strands (A, B, and E) and the other of which has one of
four strands (G, F, C, and C′), are packed face-to-face
with a well-defined hydrophobic core centered around
a conserved tryptophan. This fold is common to many
proteins of diverse function. The PKD domain represents
a novel protein domain that may be involved in protein-
protein interactions. Comparison with the binding fea-
tures of other Ig-fold proteins, including members of the
Ig superfamily, reveals that each part of the surface of
the domain, loops and sheets, can be used for interaction
with other proteins (Bork et al. 1994). Therefore, each
face of the PKD domain may be involved in either ligand
binding or interactions with adjacent PKD domains,
48 Am. J. Hum. Genet. 65:39–49, 1999
since 15 of the 16 domains in polycystin are arranged
in tandem.
Mutations in these domains may be divided into those
that act mainly by changing conformation or denaturing
their domain and those that alter the domain’s surface
properties, as has been suggested with regard to other
Ig-fold proteins (Bateman et al. 1996). Both the coding
polymorphisms and the missense mutation identified in
the PKD domains occur on surface residues. They are
therefore unlikely to have a major effect on the structure
of each domain. The W1399R mutation, despite the
change from an aromatic hydrophobic residue to a basic
one in the central part of the b strand of PKD domain
8, does not segregate with ADPKD and is found at a
low frequency in the normal population. This position
in other PKD domains in man and Fugu is not conserved
and may be occupied by an Arg residue or other basic,
polar, or hydrophobic residues (Sandford et al. 1997);
it is therefore unlikely to have major functional impor-
tance. It is possible that this change may have a modi-
fying effect on disease expression, if, for example, it al-
ters ligand-binding affinities. The ProrLeu change at
position 1786 in PKD domain 12 also does not segregate
with ADPKD in the family in which it was detected and
is therefore not disease causing. It occurs in the turn
between the F and G strands, which, in all human PKD
domains, comprises only two residues. This position is
not conserved during evolution, and Leu occupies this
position in other PKD domains. It is a rare polymor-
phism, which, again, may exert some effect on disease
expression, by altering potential PKD-protein
interactions.
Mutation R324L in PKD domain 1 is located on the
E strand. This domain is unique, since it occurs in iso-
lation and is therefore unlikely to participate in inter-
actions with other PKD domains. It is the only domain
that has a basic residue in this position. The same po-
sition in the Fugu PKD domain 1 is also occupied by a
basic residue, Lys, further suggesting the functional im-
portance of this position. The change from a basic res-
idue to a cyclic, neutral hydrophobic residue is more
likely to interfere with ligand binding than with the con-
formation of the domain itself. The E strand is therefore
a potential site of protein-protein interactions on the
PKD domain.
Mutation L845S occurs six residues N-terminal to the
start of PKD domain 2. It is therefore not possible to
determine whether it has any structural or binding sig-
nificance, but the change from a hydrophobic to a polar
residue in a position that is also conserved in Fugu po-
lycystin suggests that it is important for protein structure
or function.
Although these missense mutations fulfill most of the
criteria required in order for them to be designated as
pathological, final confirmation of their role in the path-
ogenesis of ADPKD will depend on the elucidation of
the function of both polycystin-1 and the PKD domains
and on investigation of their effects in a functional assay.
Similarly, the possibility that some of the silent poly-
morphisms detected, which generate potential cryptic
splice sites, might be pathological will await the screen-
ing, for other possible pathogenic mutations, of the rest
of the gene in these individuals.
Gene conversion has been shown to be a cause of
mutations in the PKD1 gene (Watnick et al. 1998a). Of
the four missense changes found in this study, only mu-
tation 2534TrC was found to present in the homolo-
gous genes. This was confirmed by BAC sequence
AC002039, for comparison, and by DNA from cell line
23HA.
The PKD1 gene still represents a considerable chal-
lenge for the detection of pathogenic mutations. This
challenge is mainly due to its large size, since the presence
of multiple copies no longer presents an obstacle to the
analysis of the vast majority of its coding sequence.
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